BRCA1 and ovarian carcinoma: While PARP inhibitors and BRCA1 are established core components of synthetic lethality, the studies above demonstrate their ability to mediate antitumor effects in ovarian cancer through a novel ferroptosis-dependent pathway that transcends the traditional confines of synthetic lethality interactions Figure 1.